Evotec SE (EVO)
USD 4.29
(1.42%)
USD 4.29
(1.42%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 477.11 Million EUR | -2.69% |
| 2022 | 490.29 Million EUR | 6.05% |
| 2021 | 462.3 Million EUR | 0.08% |
| 2020 | 461.95 Million EUR | 4.43% |
| 2019 | 442.36 Million EUR | 668.72% |
| 2018 | 57.54 Million EUR | 168.15% |
| 2017 | 21.46 Million EUR | 197.07% |
| 2016 | 7.22 Million EUR | -17.25% |
| 2015 | 8.73 Million EUR | 6.65% |
| 2014 | 8.18 Million EUR | 58371.43% |
| 2013 | 14 Thousand EUR | -99.66% |
| 2012 | 4.17 Million EUR | 77.03% |
| 2011 | 2.36 Million EUR | -33.18% |
| 2010 | 3.53 Million EUR | -9.18% |
| 2009 | 3.88 Million EUR | -53.66% |
| 2008 | 8.39 Million EUR | -14.58% |
| 2007 | 9.82 Million EUR | 20.95% |
| 2006 | 8.12 Million EUR | 46.92% |
| 2005 | 5.52 Million EUR | 250.57% |
| 2004 | 1.57 Million EUR | 190.39% |
| 2003 | 543.11 Thousand EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| 2001 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 428.18 Million EUR | -9.42% |
| 2024 Q1 | 472.73 Million EUR | 53.67% |
| 2023 FY | 477.11 Million EUR | -2.69% |
| 2023 Q2 | 16.64 Million EUR | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q3 | 444.45 Million EUR | 2570.84% |
| 2023 Q4 | 477.11 Million EUR | 7.35% |
| 2022 Q4 | 490.29 Million USD | 2.58% |
| 2022 Q3 | 477.98 Million EUR | 1.97% |
| 2022 Q2 | 468.74 Million EUR | 0.18% |
| 2022 Q1 | 467.92 Million EUR | 1.22% |
| 2022 FY | 490.29 Million EUR | 6.05% |
| 2021 Q4 | 462.3 Million EUR | 2.45% |
| 2021 FY | 462.3 Million EUR | 0.08% |
| 2021 Q2 | 448.94 Million EUR | -7.8% |
| 2021 Q1 | 486.93 Million EUR | 5.41% |
| 2021 Q3 | 451.25 Million EUR | 0.51% |
| 2020 Q2 | 466.21 Million EUR | 6.49% |
| 2020 Q1 | 437.82 Million EUR | -1.03% |
| 2020 Q4 | 461.95 Million EUR | 8.51% |
| 2020 Q3 | 425.73 Million EUR | -8.68% |
| 2020 FY | 461.95 Million EUR | 4.43% |
| 2019 FY | 442.36 Million EUR | 668.72% |
| 2019 Q4 | 442.36 Million EUR | 4.61% |
| 2019 Q3 | 422.85 Million EUR | 3.37% |
| 2019 Q1 | 160.09 Million EUR | 178.21% |
| 2019 Q2 | 409.06 Million EUR | 155.51% |
| 2018 Q4 | 57.54 Million EUR | 14.43% |
| 2018 Q2 | 24.29 Million EUR | 20.13% |
| 2018 FY | 57.54 Million EUR | 168.15% |
| 2018 Q1 | 20.22 Million EUR | -5.75% |
| 2018 Q3 | 50.29 Million EUR | 106.96% |
| 2017 Q2 | 6.53 Million EUR | -5.07% |
| 2017 Q1 | 6.87 Million EUR | -4.78% |
| 2017 FY | 21.46 Million EUR | 197.07% |
| 2017 Q4 | 21.46 Million EUR | 269.49% |
| 2017 Q3 | 5.8 Million EUR | -11.06% |
| 2016 Q1 | 8.27 Million EUR | -5.18% |
| 2016 FY | 7.22 Million EUR | -17.25% |
| 2016 Q4 | 7.22 Million EUR | -3.8% |
| 2016 Q3 | 7.5 Million EUR | -4.72% |
| 2016 Q2 | 7.88 Million EUR | -4.8% |
| 2015 Q1 | 8.71 Million EUR | 6.51% |
| 2015 FY | 8.73 Million EUR | 6.65% |
| 2015 Q3 | 8.9 Million EUR | 2.58% |
| 2015 Q4 | 8.73 Million EUR | -1.91% |
| 2015 Q2 | 8.67 Million EUR | -0.49% |
| 2014 Q1 | 991 Thousand EUR | 6978.57% |
| 2014 FY | 8.18 Million EUR | 58371.43% |
| 2014 Q4 | 8.18 Million EUR | 89.18% |
| 2014 Q3 | 4.32 Million EUR | 24.02% |
| 2014 Q2 | 3.48 Million EUR | 252.07% |
| 2013 Q1 | 4.14 Million EUR | -0.69% |
| 2013 Q4 | 14 Thousand EUR | -99.66% |
| 2013 FY | 14 Thousand EUR | -99.66% |
| 2013 Q3 | 4.05 Million EUR | -1.1% |
| 2013 Q2 | 4.1 Million EUR | -1.11% |
| 2012 Q4 | 4.17 Million EUR | -1.07% |
| 2012 Q1 | 4.31 Million EUR | 82.71% |
| 2012 Q2 | 5.31 Million EUR | 23.35% |
| 2012 Q3 | 4.22 Million EUR | -20.61% |
| 2012 FY | 4.17 Million EUR | 77.03% |
| 2011 Q3 | 3 Million EUR | -0.03% |
| 2011 Q4 | 2.36 Million EUR | -21.39% |
| 2011 Q1 | 3.01 Million EUR | -14.58% |
| 2011 Q2 | 3 Million EUR | -0.46% |
| 2011 FY | 2.36 Million EUR | -33.18% |
| 2010 Q4 | 3.53 Million EUR | 15.88% |
| 2010 FY | 3.53 Million EUR | -9.18% |
| 2010 Q3 | 3.04 Million EUR | -0.78% |
| 2010 Q2 | 3.07 Million EUR | -17.51% |
| 2010 Q1 | 3.72 Million EUR | -4.24% |
| 2009 Q4 | 3.88 Million EUR | -48.71% |
| 2009 Q1 | 8.24 Million EUR | -1.81% |
| 2009 Q2 | 7.45 Million EUR | -9.56% |
| 2009 Q3 | 7.58 Million EUR | 1.74% |
| 2009 FY | 3.88 Million EUR | -53.66% |
| 2008 Q2 | 10.57 Million EUR | 8.84% |
| 2008 Q4 | 8.39 Million EUR | -14.95% |
| 2008 Q3 | 9.86 Million EUR | -6.7% |
| 2008 FY | 8.39 Million EUR | -14.58% |
| 2008 Q1 | 9.71 Million USD | -6.49% |
| 2007 FY | 9.82 Million EUR | 20.95% |
| 2007 Q3 | 4.91 Million EUR | 0.0% |
| 2007 Q4 | 10.39 Million EUR | 111.4% |
| 2006 Q3 | 2.76 Million EUR | 2.35% |
| 2006 Q2 | 2.7 Million EUR | 19.82% |
| 2006 Q4 | 9.24 Million EUR | 233.89% |
| 2006 FY | 8.12 Million EUR | 46.92% |
| 2006 Q1 | 2.25 Million EUR | -8.07% |
| 2005 FY | 5.52 Million EUR | 250.57% |
| 2005 Q2 | 1.92 Million EUR | -4.59% |
| 2005 Q1 | 2.01 Million EUR | 27.61% |
| 2005 Q4 | 2.45 Million EUR | 0.0% |
| 2004 Q1 | 1.29 Million EUR | 138.66% |
| 2004 FY | 1.57 Million EUR | 190.39% |
| 2004 Q4 | 1.57 Million EUR | 0.0% |
| 2004 Q2 | 1.47 Million EUR | 13.85% |
| 2003 FY | 543.11 Thousand EUR | 0.0% |
| 2003 Q4 | 543.11 Thousand EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| 2001 FY | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Theratechnologies Inc. | 51.26 Million USD | -830.75% |
| Safety Shot Inc | 304.9 Thousand USD | -156377.877% |
| Biofrontera Inc. | 804 Thousand USD | -59242.289% |
| DURECT Corporation | 2.7 Million USD | -17557.735% |
| Cosmos Health Inc. | 3.03 Million USD | -15618.563% |
| Cronos Group Inc. | 1.55 Million USD | -30503.72% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 4.872% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | 4.254% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -1295.472% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -104759.78% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -685.434% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -4551.121% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -88412.249% |
| Alpha Teknova, Inc. | 13.25 Million USD | -3500.574% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -3480.309% |
| SCYNEXIS, Inc. | 12.15 Million USD | -3823.941% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | -54.072% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -548304.598% |
| Dynavax Technologies Corporation | 252.41 Million USD | -89.017% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -423.861% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -141901.423% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | -295.911% |
| Shineco, Inc. | 10.01 Million USD | -4662.865% |
| Indivior PLC | 235.66 Million USD | -102.452% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Radius Health, Inc. | 339.66 Million USD | -40.465% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -88412.249% |
| Incannex Healthcare Limited | 210 Thousand USD | -227096.19% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -407238.917% |
| Alimera Sciences, Inc. | 64.48 Million USD | -639.835% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -353083.457% |
| Alvotech | 1.02 Billion USD | 53.578% |
| Journey Medical Corporation | 14.62 Million USD | -3162.974% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -6857.659% |
| Embecta Corp. | 1.62 Billion USD | 70.646% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2121906.76% |
| Procaps Group, S.A. | 28.41 Million USD | -1579.38% |
| PainReform Ltd. | 30 Thousand USD | -1590273.333% |
| Harrow Health, Inc. | 183.17 Million USD | -160.472% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -1337.258% |
| OptiNose, Inc. | 611 Thousand USD | -77987.07% |
| Kamada Ltd. | 7.43 Million USD | -6314.52% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -3632.061% |
| Phibro Animal Health Corporation | 458.28 Million USD | -4.107% |
| Procaps Group S.A. | 28.41 Million USD | -1579.38% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -7204.225% |
| Talphera, Inc. | - USD | -Infinity% |
| Viatris Inc. | 16.18 Billion USD | 97.053% |
| Rockwell Medical, Inc. | 8.29 Million USD | -5653.19% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -4286.43% |
| Tilray Brands, Inc. | 287.93 Million USD | -65.701% |
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | 2.623% |
| PetIQ, Inc. | 437.82 Million USD | -8.974% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -84.712% |
| Assertio Holdings, Inc. | 38.51 Million USD | -1138.801% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 22.562% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -1356.386% |
| Hempacco Co., Inc. | 5.93 Million USD | -7944.376% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 7.14% |
| Alvotech | 1.02 Billion USD | 53.578% |
| Currenc Group, Inc. | 2.5 Million USD | -18931.39% |
| Evoke Pharma, Inc. | 5 Million USD | -9442.24% |
| Flora Growth Corp. | 942 Thousand USD | -50548.832% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2121906.76% |
| Evolus, Inc. | 120.35 Million USD | -296.407% |
| HUTCHMED (China) Limited | 48.18 Million USD | -890.085% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 19.024% |
| Akanda Corp. | 2.49 Million USD | -19006.223% |